Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Mok on Plasma Testing Approaches in Lung Cancer

August 9th 2013

Tony S.K. Mok, BMSc, MD, FRCPC, from the Chinese University of Hong Kong, discusses different plasma testing approaches for patients with lung cancer.

Dr. Wakelee on Nintedanib Plus Chemotherapy in NSCLC

August 9th 2013

Heather Wakelee, MD, from the Stanford University School of Medicine, describes two phase III trials that focused on the second-line nintedanib plus chemotherapy to treat patients with advanced non-small cell lung cancer.

Dr. Scagliotti on Lung Cancer Treatment-Related Toxicities

August 7th 2013

Giorgio V. Scagliotti, MD, PhD, Head, from the University of Turin, Italy, discusses toxicities related to chemotherapy and surgery in patients with lung cancer.

Dr. Herbst on Immunotherapy in Lung Cancer

August 2nd 2013

Roy S. Herbst, MD, PhD, chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses immunotherapy for patients with lung cancer.

Cryoablation May Offer Option for Metastatic Lung Tumors

August 1st 2013

The results of the first prospective multicenter trial of cryoablation in lung cancer show that this emerging treatment may be a safe, effective, and minimally invasive method of helping a specific group of patients with advanced disease.

Dr. Bradley on Radiation Therapy in Lung Cancer

July 29th 2013

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses ongoing research involving radiation therapy for lung cancer.

Second-Generation ALK Inhibitors Show Promise in Early-Stage NSCLC Trials

July 29th 2013

Although crizotinib (Xalkori) is highly effective in treating patients with advanced ALK-positive non–small cell lung cancer (NSCLC), most patients develop resistance to the drug.

Dr. Lynch Accepts His 'Giants of Cancer Care' Award

July 29th 2013

Thomas J. Lynch, Jr., MD, from the Yale Cancer Center, pioneered the use of molecular testing for EGFR mutations in lung cancer. In July 2013, he was honored by OncLive as one of the "Giants of Cancer Care."

Dr. Gandara Spotlights the Giants of Cancer Care

July 26th 2013

David R. Gandara, MD, from the UC Davis Cancer Center, discusses the 2013 recipient of the Giants in Cancer Care award in the field of thoracic oncology: Thomas J. Lynch, Jr., MD.

Dr. Carbone on Genetic Testing Availability and Accuracy

July 25th 2013

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, describes variations in the accuracy and availability of genetic testing technologies.

Dr. Shaw Compares Crizotinib and Chemotherapy in NSCLC

July 19th 2013

Lead author, Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital, reviews the first published results from a randomized phase III trial investigating crizotinib in patients with ALK-positive non-small cell lung cancer.

Dr. Ramalingam on Hsp90 Inhibition With Ganetespib

July 18th 2013

Suresh S. Ramalingam, MD, from the Winship Cancer Institute of Emory University, discusses the role of heat shock proteins in normal cells and their potential role in treating cancer.

Matthew Lara on Younger Vs Older Patients With NSCLC

July 17th 2013

Primo Lara, MD, and his son, Matthew Stephen Lara, discuss an analysis of predictors of survival for younger patients with non-small cell lung cancer.

FDA Approves Afatinib for Metastatic NSCLC

July 12th 2013

The FDA has approved afatinib, along with a companion diagnostic, to treat patients with metastatic non-small cell lung cancer who express specific types of EGFR mutations.

Dr. Gandara on the Heat Shock Protein 90 Inhibitor Ganetespib

July 1st 2013

David R. Gandara, MD, from UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.

Potential Biomarkers Identified for Predicting Response to Drugs Targeting KRAS-Mutated NSCLC

July 1st 2013

Investigators identified three proteins that were able to predict response to treatment with a MEK inhibitor plus a PI3 kinase inhibitor-an investigational approach to NSCLC, including some KRAS-mutated cancers.

Dr. Bradley on the Background of the RTOG 0617 Study

June 18th 2013

Jeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses the background of the phase III RTOG 0617 study.

New Guidelines, Therapies in Spotlight at PER Congress

June 18th 2013

Discussions about new guidelines on molecular testing in patients with lung cancer and a keynote address from prominent researcher Tony S. Mok, MD, will be among the highlights of the upcoming 14th International Lung Cancer Congress.

Lack of Discontinuation of Statin Therapy After Diagnosis of End-Stage Cancer

June 14th 2013

The diagnosis of end-stage cancer rarely led to the clinically indicated discontinuation of statin therapy when prescribed for primary prevention.

Dr. Camidge on Crizotinib as a ROS1 Inhibitor in NSCLC

June 13th 2013

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the use of crizotinib as a ROS1 inhibitor in non-small cell lung cancer (NSCLC).

NEXT PAGE
PREVIOUS PAGE